ClinicalTrials.gg
RecruitingNCT06719791Updated Dec 31, 2024

Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)

An Early Phase 1 interventional study of Sirolimus in Epilepsy, Drug Resistant, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Xuanwu Hospital, Beijing · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.

Planned enrollment
5th of 12
15 · median 13
Started
2024
with 11 others
Phase 1
2 of 15
2 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
11th of 15
by date

Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 12 that started in 2024, is one of 2 in phase 1, reaches primary completion later than 8 of the 11 other live ones, and was the 11th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the clinical efficacy of sirolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.

Read the detailed description

Previous research has shown that the mTOR pathway is involved in the "epilepsy memory" process. Associating the acute seizures of the mouse kainic acid epilepsy model with a specific odor stimulus can lead to specific induction of epileptic seizures by this odor stimulus two weeks later. After epileptic seizures induced by a specific odor stimulus, the expression of the memory-related molecule pmTOR in the mouse hippocampus changes in a time-dependent manner, indicating that the mTOR signaling pathway is involved in the reconsolidation process of epilepsy memory. Further intervention in the reconsolidation process of epilepsy memory with the mTOR inhibitor sirolimus (Rap) found that administering the drug within the memory consolidation window (5 min) could effectively intervene in the reinduction of epilepsy, while administering the drug outside the memory consolidation window (9 h) could not intervene. Professor Huang Zhuo's team validated the above experimental results using a conditioned epilepsy memory mouse model. Clinical experiments have found that administering the mTOR pathway inhibitor everolimus immediately after an epileptic seizure in patients can significantly reduce the interictal brain electrical activity, showing promising epilepsy treatment effects. However, this study only involved a single drug treatment, the treatment duration was short, and only the changes in epileptiform discharges after treatment with everolimus in epileptic patients were evaluated at the electrophysiological level, without evaluating the control efficacy on seizure symptoms in patients after repeated seizures with a sufficient course of treatment.

Therefore, inhibiting the mTOR signaling pathway within a specific time window by intervening in the reconsolidation of the current epileptic event holds promise as a new strategy to alleviate subsequent seizures. This strategy is expected to be applicable to a broader range of treatments for refractory epilepsy, and administering medication only during epileptic events is anticipated to achieve more efficient therapeutic effects.

Everolimus (sirolimus) is an inhibitor of the mammalian target of rapamycin (mTOR). In studies using animal models of tuberous sclerosis complex (TSC), mTOR inhibitors have been found to significantly reduce the frequency of epileptic seizures; furthermore, everolimus is currently undergoing phase III clinical trials as an adjunctive treatment for refractory epilepsy associated with TSC. Evidence from various animal models of epilepsy, including genetic epilepsy (such as in WAG/Rij rats) and acquired epilepsy (such as those induced by kainic acid or pilocarpine), also suggests the involvement of the mTOR signaling pathway in these forms of epilepsy and the broad inhibitory effects of mTOR inhibitors on epileptic seizures.

Based on the "epilepsy memory" mechanism, combining everolimus with a memory reconsolidation paradigm holds promise as an effective adjunctive treatment for refractory epilepsy. Evaluating its efficacy and safety not only helps establish its value in epilepsy treatment but also provides important guidance for clinical practice, crucial for the transition from basic research to clinical application.

03

Conditions studied

  • Epilepsy, Drug Resistant

Keywords

  • Sirolomus
  • Focal Refractory Epilepsy
  • mTOR pathway
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-60 years of age.
  • Meet the 2017 International League Against Epilepsy (ILAE) diagnostic criteria for for focal seizures or focal seizures progressing to bilateral tonic-clonic seizures.
  • Diagnosed with epilepsy, having used at least two AEDs without effectiveness for 2 years. No drug interaction between current AEDs and sirolomus, and a stable dose for at least 12 weeks prior to enrollment.
  • Seizure duration ≥1 minute, with accompanying sensory impairment.
  • At least 6 focal seizures within the 12 weeks preceding enrollment.
  • EEG or MRI/CT results within the past 2 years, confirming the diagnosis of focal epilepsy.
  • The use of vagus nerve stimulation (VNS) and deep brain stimulation (DBS) is permitted, need to implant at least 5 months and stable for at least 12 weeks before enrollment.The parameters should keep unchanged until the end of the study.
  • signed.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations
  • Psychogenic non-epileptic seizures within 12 months;
  • Treatable causes of epilepsy (such as metabolic disorders, toxicity, infections, space occupying lesions, or identified genetic abnormalities)
  • Patients with only non-motor focal seizures, as classified by the 2017 ILAE.
  • Seizure clusters within the 12 months.
  • Tonic-clonic status epilepticus within12 months.
  • Free of major medical illnesses including:
  • Cerebrovascular events within the past 6 months, including cerebral infarction, cerebral hemorrhage, and , or those with progressive intracranial lesions.
  • Severe uncontrolled diseases, such as immunodeficiency disorders, liver or kidney diseases, acute infections, or advanced-stage tumors.
  • Severe cardiovascular or peripheral vascular diseases, such as those classified as Class III-IV, or those with malignant arrhythmias (e.g., Long syndrome, Brugada syndrome, and conduction block), or any other abnormalities, or who have had a myocardial infarction within the past 3 months before screening
  • Participants with a history of medical conditions or surgeries that, in the investigator's judgment, could affect the absorption, distribution, or metabolism of the study drug (e.g., active peptic ulcers, ulcerative colitis, Crohn's disease, or bowel obstruction) or those with difficulty swallowing.
  • Participants with any medical condition, mental health status, cognitive impairment, or intellectual disability that the investigator believes could increase the risk to the participant or interfere with their ability to participate in the clinical trial.
  • Severe allergic reactions to any component of sirolimus, or have .
  • Participants meeting any of the following laboratory criteria: (ALT) >2× (ULN), aspartate aminotransferase (AST) >2× ULN, alkaline phosphatase (ALP) >2× ULN, count \<80×10\^9/L, \<1.8×10\^9/L, or (CLcr) \<30 mL/min (calculated by the Cockcroft-Gault formula).
  • In the period of pregnancy, childbirth, lactation.
  • Alcohol abuse or drug misuse within 2 years prior to medication.
  • Participation in another clinical study within 3 months;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Open label single arm, drug sirolomus

    All subjects will receive the experimental drug

    Drug: Sirolimus

Interventions

  • Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Seizure Frequency Per 28 Days

    Percent change in 28-day frequency of seizures during the 40 week treatment and follow-up period relative to baseline

    Time frame: assessed per 28 days during the treatment.

  2. 50% Seizure Responder Rate

    The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency.

    Time frame: short-term treatment period (ending at 3 months); long-term follow-up period (ending at 12 months).

Secondary outcomes

  1. Seizure Severity

    The percent change from baseline in seizure severity evaluated by Liverpool seizure severity scale (LSSS) .

    Time frame: Baseline observation period; short-term treatment period (ending at 3 months); long-term follow-up period (ending at 12 months).

  2. Life quality evaluation

    Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31) score.

    Time frame: Baseline observation period; short-term treatment period (ending at 3 months); long-term follow-up period (ending at 12 months).

  3. Adverse Events

    Rate of adverse events which were judged to be study-related throughout the study.

    Time frame: through study completion, 12 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2024
First posted
Dec 6, 2024
StartActual
Dec 23, 2024
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2028
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06719791
Collaborators
Peking University
Responsible party
Liankun_Ren (Professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Dec 6, 2024
Start date
Dec 23, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Dec 31, 2024

Study contacts

Liankun Ren, MD
Contact
renlk2022@outlook.com
+86 13681576621
Liankun Ren, MD
principal investigator · Xuanwu Hospital, Beijing
Zhuo Huang, PhD
principal investigator · Peking University School of Pharmaceutical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion